Top Suppliers:I want be here
Related CAS#:
2743204-16-0 2739884-26-3
2738753-98-3 2740005-12-1
2741419-64-5 2755567-17-8
2755567-24-7 1373446-37-7
2755594-45-5 2755531-94-1

53956-04-0

53956-04-0 structure
53956-04-0 structure
Name Glycyrrhizic acid ammonium salt
Synonyms AMMONIATED GLYCYRRHIZIN, NATURAL
3-O-(2-O-β-D-Glucopyranuronosyl-α-D-glucopyranuronosyl)-18β-glycyrrhetinic acid ammonium salt
GLYCAMIL
MONOAMMONIATED GLYCYRRHIZINATE
GLYCYRRHIZIC ACID AMMONIUM
Monoammonium glycyrrhizinate Glycyrrhizic acid ammonium
MONOAMMONIUM GLYCYRRHIZINATE SODIUM GLYCYRRHIZINTE
ammonium glycyrrhizinate
MFCD00167400
MONOAMMONIUM GLYCRRHIZINATE
Glycyrrhizin Monoammonium Salt Hydrate
MONOAMMONIUM GLYCYRRHIZINATE
Glycyrrhizic Acid Monoammonium Salt Hydrate
glycyrrhizin monoammonium salt
GLYCYRRHIZICAMMONIUM
Magnasweet
ammoniate
Glycyrrhizate monoammonium
Monoammoniumglycyrrhetate
alpha.-D-Glucopyranosiduronicacid,(3.beta.,20.beta.)-20-cboxy-11-oxo-30-norolean-12-en-3-yl2-O-.beta.-D-glucopyranuronosyl-,monoammoniumsalt
Glycyrrhizin ammonium
GLYCYRRHIZIN, AMMONIATED [GLYCYRRHIZINIC ACID, MONOAMMONIUM SALT]
Glycyrrhiz
Glycyrrhizic acid ammonium salt 53-0
GLYCYRRHIZIN, AMMONIATED
Ammonium glycyrrhizate
aMMoniuM (2S,3S,4S,5R,6S)-5-((2R,3R,4S,5S,6S)-6-cboxy-3,4,5-trihydroxytetrahydro-2H-pyran-2-yloxy)-6-((3S,6,6bS,8aS,11S,12,14,14bS)-11-cboxy-4,4,6a,6b,8a,11,14b-htaMethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydrop
GLYCYRRHIZINICACIDAMMONIUMSALT
GLYCYRRHIZIC ACID,NH4
Glycyrrhizine ammonium salt
Glycyrrhizic acid monoammonium salt trihydrate
GLYCYRRHIZIN AMMONIUM SALT
α-D-Glucopyranosiduronic acid, (3,20)-20-cboxy- 11-oxo-30-norolean-12-en-3-yl 2-O-D-glucopyranuronosyl-, monoammonium salt
MonoaMMoniuM 18β-glycyrrhizinate
glycyrram
EINECS 258-887-7
(2S,3S,4S,5R,6S)-6-[[(3S,4aS,6,6bS,8,11S,12,14aS,14bS)-11-cboxy-4,4,6a,6b,8a,11,14b-htamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-5-[(2R,3R,4S,5S,6S)-6-cboxy-3,4,5-trihydroxy-oxan-2-yl]oxy-3,4-dihydroxyoxane-2-cboxylic acid azane
Ammoniumglycynhizinato
GLYCYRRHIZIC ACID AMMONIUM SALT
AMMONIATEDGLYCERRHIZIN
Glycyrrhizic acid, aMMoniuM salt, trihydrate / Glycyrrihizin
glycyrrhizic acid monoammonium salt
Glycyrrhizic acid MonoaMMoniuM salt trihydrate, R
(3β)-30-Hydroxy-11,30-dioxoolean-12-en-3-yl 2-O-β-D-glucopyranuronosyl-α-D-glucopyranosiduronic acid diammoniate
monoammoniumglycyrrhetat
Monoammonium Glycyrrhizinate Hydrate
AMMONIUM 10-[6-CBOXY-3-(6-CBOXY-3,4,5-TRIHYDROXY-OXAN-2-YL)OXY-4,5-DIHYDROXY-OXAN-2-YL]OXY-2,4A,6A,6B,9,9,12A-HTAMETHYL-13-OXO-3,4,5,6,6A,7,8,8A,10,11,12,14B-DODECAHYDRO-1H-PICENE-2-CBOXYLATE
GLYCYRRHIZIN AMMONIACAL
alpha-D-Glucopyranosiduronic acid, (3-beta,20-beta)-20-cboxy-11-oxo-30-norolean-12-en- 3-yl 2-O-beta-D-glucopyranuronosyl-, ammoniate
Glycyrrhizic Acid Monoammonium Salt Glycyrrhizin Monoammonium Salt
AMMONIATED GLYCYRRHIZIN
GLYCYRRHIZIC ACID MONOAMMONIUM SALT
AMMONIUMGLYCYRRHIZIN
GLYCYRRHIZIC ACID, AMMONIUM SALT(RG)
alpha.-D-Glucopyranosiduronic acid, (3.beta.,20.beta.)-20-cboxy-11-oxo-30-norolean-12-en-3-yl 2-O-.beta.-D-glucopyranuronosyl-, monoammonium salt
3-O-(2-O-BETA-D-GLUCOPYRANURONOSYL-ALPHA-D-GLUCOPYRANURONOSYL)-18BETA-GLYCYRRHETINIC ACID AMMONIUM SALT
Glycyrrhizic acid ammonium salt from glycyrrhiza
GLYCERRHIZICACIDMONOAMMONIUMSALT
monoammonium glycyrrhizlnate
(2S,3S,4S,5R,6S)-6-[[(3S,4aS,6,6bS,8,11S,12,14aS,14bS)-11-cboxy-4,4,6a,6b,8a,11,14b-htamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-5-[(2R,3R,4S,5S,6S)-6-cboxy-3,4,5-trihydroxy-oxan-2-yl]oxy-3,4-dihydroxy-oxane-2-cboxylic acid
20β-Cboxy-11-oxo-30-noroleana-12-ene-3β-yl 2-O-(β-D-glucopyranuronosyl)-α-D-glucopyranosiduronic acid/ammonia,(1:x)
GLYCYRRHIZINATE MONOAMMONIUM SALT
ammoniumglycyrrhizate
Monoammoniumglycyrrhizinate
GLYCYRRHIZIC ACID, NH4
3-O-(2-O-beta-D-Glucopyranuronosyl-alpha-D-glucopyranuronosyl)-18beta-g lycyrrhetinic acid ammonium salt
monoammoniumglycyrrhizate
Description Monoammonium glycyrrhizinate hydrate has various pharmacological actions such as anti-inflammatory, antiallergic, antigastriculcer, and antihepatitis activities.
Related Catalog
In Vivo The increase of the lung W/D weight ratios is significantly reduced by high and medium dose of MAG (10 and 30mg/kg) administration. Pretreatment with MAG (10 and 30mg/kg) efficiently reduces the production of TNF-α and IL-1β. MAG (10, 30mg/kg) significantly decreases NF-κB p65 protein expression, compared with LPS. On the contrary, LPS significantly reduces IκB-α protein expression compared with the control group, whereas MAG (10 and 30mg/kg) significantly increased IκB-α expression, compared with the LPS group[1]. Low- and high-dose MAG treatment significantly reduces the AST, ALT, TBIL, and TBA levels at 14 and 21 d time points when compared with that of the RIF and INH group, suggesting the protective effect of MAG on RIF- and INH-induced liver injury. MAG treatment groups elevate the hepatic GSH level at 7, 14, and 21 d time points and markedly reduce the MDA level at 14 and 21 d time points in RIF- and INH-treated rats, suggesting the protective effect of MAG in RIF- and INH induced liver injuries[2].
Animal Admin Mice[1] In this study, BALB/c mice (male, 6-8weeks old, and 20-25 g) are used. Mice are randomly divided into five groups: control group, LPS group, and LPS + Monoammonium glycyrrhizinate (MAG: 3, 10, and 30mg/kg) groups. Each group contains eight mice. Mice are anesthetized with intraperitoneal injection of sodium pentobarbital (50mg/kg). Before inducing acute lung injury, the mice are given intraperitoneal injection with MAG (3, 10, and 30mg/kg). One hour later, LPS (5mg/kg) is instilled intratracheally to induce acute lung injury. Normal mice are given PBS[1]. Rats[2] Male Wistar rats (180-220 g) are used. Rats are randomly divided into four groups, i.e., control group, RIF and INH group, MAG low-dose group, and MAG high-dose group, each group has 15 rats. Rats in the RIF and INH group receive RIF (60 mg/kg) and INH (60 mg/kg) by gavage administration once daily; rats in MAG groups are pretreated with MAG at the doses of 45 or 90 mg/kg, RIF (60 mg/kg) and INH (60 mg/kg) are given 3 h after MAG administration; rats in the control group are treated with saline. To evaluate the dynamic effect of drugs, rats in each group are sacrificed on 7, 14, and 21 d after drug administration[2].
References

[1]. Huang X, et al. Anti-Inflammatory Effects of Monoammonium Glycyrrhizinate on Lipopolysaccharide-Induced Acute Lung Injury in Mice through Regulating Nuclear Factor-Kappa B Signaling Pathway. Evid Based Complement Alternat Med. 2015;2015:272474.

[2]. Zhou L, et al. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver. Pharm Biol. 2016;54(6):931-7.
Density 1.43g/cm3
Boiling Point 971.4ºC at 760mmHg
Melting Point 209ºC
Molecular Formula C42H65NO16
Molecular Weight 839.96
Flash Point 288.1ºC
PSA 272.70000
LogP 0.32860
Index of Refraction 49 ° (C=1.5, EtOH)
Storage condition 2-8°C
Water Solubility Slightly soluble in water, very slightly soluble in anhydrous ethanol, practically insoluble in acetone. It dissolves in dilute solutions of acids and of alkali hydroxides.

CHEMICAL IDENTIFICATION

RTECS NUMBER :
LZ6500000
CHEMICAL NAME :
alpha-D-Glucopyranosiduronic acid, (3-beta,20-beta)-20-carboxy-11-oxo-30-norolean-12-en- 3-yl 2-O-beta-D-glucopyranuronosyl-, ammoniate
CAS REGISTRY NUMBER :
53956-04-0
LAST UPDATED :
199712
DATA ITEMS CITED :
14
MOLECULAR FORMULA :
C42-H62-O16.H3-N
MOLECULAR WEIGHT :
840.08

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>300 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
9818 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
540 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
224 mg/kg/26W-C
TOXIC EFFECTS :
Cardiac - changes in heart weight Kidney, Ureter, Bladder - changes in bladder weight Endocrine - changes in adrenal weight
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
840 mg/kg/30D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse Blood - changes in leukocyte (WBC) count Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
350 gm/kg
SEX/DURATION :
male 10 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
235 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
7479 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
Dominant lethal test

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
350 gm/kg/10W (Continuous)
REFERENCE :
NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information. Volume(issue)/page/year: PB279-650 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5765 No. of Facilities: 3 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 221 (estimated) No. of Female Employees: 144 (estimated)
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes Xn
RIDADR UN 3077 9 / PGIII
WGK Germany 2
RTECS LZ6500000
Precursor  0

DownStream  1

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:53956-04-0 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 53956-04-0 | Chemsrc address: https://m.chemsrc.com/en/baike/831808.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved